Clinical Trial Update: Temozolomide Plus Irinotecan in Treating Patients With Recurrent Malignant Glioma [Phase 1]

View source ↗

Summary

A phase 1 clinical trial evaluating the combination of temozolomide and irinotecan in patients with recurrent malignant glioma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Glioma

Drugs mentioned

• Camptosar (irinotecan)
• Temodar (Temozolomide)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Conditions: Brain and Central Nervous System Tumors | Phase 1 | Status: COMPLETED